Sprout BioVentures

The firm operates an asset-formation model within the Cambridge-Boston biotechnology cluster, building companies around specific scientific projects sourced from Harvard, MIT, and affiliated research institutions. Sprout enters at the conceptual or preclinical stage, often before a startup has a management team or a formal pitch deck. This approach positions the firm as the first institutional capital into newco formation rather than as a passive participant in competitive Series A rounds.

Sprout targets the earliest phase of biotech venture capital: seed formation, startup creation, and early Series A rounds. The firm provides capital at the point of highest technical risk — moving academic discoveries into a corporate structure with initial management, intellectual property licensing, and first scientific workplans. This precludes the firm from later-stage crossover rounds or public-market investing.